open access

Vol 91, No 6 (2020)
REVIEW PAPERS Gynecology
Published online: 2020-06-30
Get Citation

The usefulness of periostin determination in gynecology and obstetrics

Christopher Kobierzycki, Krzysztof J. Latkowski, Piotr Dziegiel
DOI: 10.5603/GP.2020.0064
·
Pubmed: 32627156
·
Ginekol Pol 2020;91(6):364-351.

open access

Vol 91, No 6 (2020)
REVIEW PAPERS Gynecology
Published online: 2020-06-30

Abstract

Periostin (POSTN) is a multifunctional glycoprotein that belongs to the group of extracellular matrix (ECM) proteins. Due
to the molecular structure, cellular interactions, tissue locations as well functions of POSTN, we realize that its pivotal
role is organization and regulation of ECM microenvironment. In available databases there is a lack of data summarizing
current knowledge about POSTN expression in the field of gynecology and obstetrics. We conducted a search in PubMed
of the National Library of Medicine and Google Scholar. Databases were extensively searched for all original and review
articles/book chapters published in English until December 2019 and related to periostin expression. All relevant articles
were reviewed and presented as appropriate.
In the field of POSTN expression there is only one paper evaluating its involvement in cervical cancer cell metabolism and
only two studies analyzing its myometrial commitment: maintenance during pregnancy and induction of parturition in
physiology as well control of fibroids biology in pathology. Much more attention has been devoted to the expression of
described protein in the endometriosis, and above all in ovarian cancer. Finally, a few studies carried out among pregnant
women were presented.
In this review study we presented current knowledge about periostin expression in the field of gynecology and obstetrics.
Many achieved results are interesting and further studies are needed to verify some hypotheses. Structure, signaling
pathways as well many functions of periostin are well-described. However, as it was clearly shown there is a lot of unknown
issues which are waiting to be explored.

Abstract

Periostin (POSTN) is a multifunctional glycoprotein that belongs to the group of extracellular matrix (ECM) proteins. Due
to the molecular structure, cellular interactions, tissue locations as well functions of POSTN, we realize that its pivotal
role is organization and regulation of ECM microenvironment. In available databases there is a lack of data summarizing
current knowledge about POSTN expression in the field of gynecology and obstetrics. We conducted a search in PubMed
of the National Library of Medicine and Google Scholar. Databases were extensively searched for all original and review
articles/book chapters published in English until December 2019 and related to periostin expression. All relevant articles
were reviewed and presented as appropriate.
In the field of POSTN expression there is only one paper evaluating its involvement in cervical cancer cell metabolism and
only two studies analyzing its myometrial commitment: maintenance during pregnancy and induction of parturition in
physiology as well control of fibroids biology in pathology. Much more attention has been devoted to the expression of
described protein in the endometriosis, and above all in ovarian cancer. Finally, a few studies carried out among pregnant
women were presented.
In this review study we presented current knowledge about periostin expression in the field of gynecology and obstetrics.
Many achieved results are interesting and further studies are needed to verify some hypotheses. Structure, signaling
pathways as well many functions of periostin are well-described. However, as it was clearly shown there is a lot of unknown
issues which are waiting to be explored.

Get Citation

Keywords

periostin; POSTN; cancer; neoplasm; endometriosis; myoma; leiomyoma; fibroid; gestation; pregnancy; miscarriage

About this article
Title

The usefulness of periostin determination in gynecology and obstetrics

Journal

Ginekologia Polska

Issue

Vol 91, No 6 (2020)

Pages

364-351

Published online

2020-06-30

DOI

10.5603/GP.2020.0064

Pubmed

32627156

Bibliographic record

Ginekol Pol 2020;91(6):364-351.

Keywords

periostin
POSTN
cancer
neoplasm
endometriosis
myoma
leiomyoma
fibroid
gestation
pregnancy
miscarriage

Authors

Christopher Kobierzycki
Krzysztof J. Latkowski
Piotr Dziegiel

References (38)
  1. Morra L, Moch H. Periostin expression and epithelial-mesenchymal transition in cancer: a review and an update. Virchows Archiv. 2011; 459(5): 465–475.
  2. Horiuchi K, Amizuka N, Takeshita S, et al. Identification and Characterization of a Novel Protein, Periostin, with Restricted Expression to Periosteum and Periodontal Ligament and Increased Expression by Transforming Growth Factor β. Journal of Bone and Mineral Research. 1999; 14(7): 1239–1249.
  3. Ye D, Shen Z, Qiu S, et al. Role and underlying mechanisms of the interstitial protein periostin in the diagnosis and treatment of malignant tumors (Review). Oncology Letters. 2017.
  4. Ruan K, Bao S, Ouyang G. The multifaceted role of periostin in tumorigenesis. Cellular and Molecular Life Sciences. 2009; 66(14): 2219–2230.
  5. Ratajczak-Wielgomas K, Dziegiel P. The role of periostin in neoplastic processes. Folia Histochemica et Cytobiologica. 2015; 53(2): 120–132.
  6. Lister N, Clemson M, Morris K. RNA-directed epigenetic silencing of Periostin inhibits cell motility. Royal Society Open Science. 2015; 2(6): 140545.
  7. Han X, Wang Q, Wang Y, et al. Long non‐coding RNA metastasis‐associated lung adenocarcinoma transcript 1/microRNA‐202‐3p/periostin axis modulates invasion and epithelial–mesenchymal transition in human cervical cancer. Journal of Cellular Physiology. 2019; 234(8): 14170–14180.
  8. Hiroi H, Momoeda M, Nakazawa F, et al. Expression and regulation of periostin/OSF-2 gene in rat uterus and human endometrium. Endocr J. 2008; 55(1): 183–189.
  9. Shen L, Liu P, Zhang P, et al. Characterization of periostin expression in human endometrium and endometriotic lesions. Gynecological Endocrinology. 2012; 28(10): 815–818.
  10. Xu X, Zheng Q, Zhang Z, et al. Periostin Enhances Migration, Invasion, and Adhesion of Human Endometrial Stromal Cells Through Integrin-Linked Kinase 1/Akt Signaling Pathway. Reproductive Sciences. 2015; 22(9): 1098–1106.
  11. Zheng Qm, Lu Jj, Zhao J, et al. Periostin Facilitates the Epithelial-Mesenchymal Transition of Endometrial Epithelial Cells through ILK-Akt Signaling Pathway. BioMed Research International. 2016; 2016: 1–8.
  12. Logan P, Yango P, Tran N. Endometrial Stromal and Epithelial Cells Exhibit Unique Aberrant Molecular Defects in Patients With Endometriosis. Reproductive Sciences. 2017; 25(1): 140–159.
  13. Ganieva U, Nakamura T, Osuka S, et al. Involvement of Transcription Factor 21 in the Pathogenesis of Fibrosis in Endometriosis. The American Journal of Pathology. 2020; 190(1): 145–157.
  14. Liu L, Li H, Dargahi D, et al. HoxA13 Regulates Phenotype Regionalization of Human Pregnant Myometrium. The Journal of Clinical Endocrinology & Metabolism. 2015; 100(12): E1512–E1522.
  15. Jamaluddin M, Ko YA, Kumar M, et al. Proteomic Profiling of Human Uterine Fibroids Reveals Upregulation of the Extracellular Matrix Protein Periostin. Endocrinology. 2017; 159(2): 1106–1118.
  16. Chen X, Huo L, Ren L, et al. Polycystic Ovary Syndrome is Associated with Elevated Periostin Levels. Experimental and Clinical Endocrinology & Diabetes. 2018; 127(09): 571–577.
  17. Ricciardelli C, Lokman NA, Ween MP, et al. WOMEN IN CANCER THEMATIC REVIEW: Ovarian cancer–peritoneal cell interactions promote extracellular matrix processing. Endocrine-Related Cancer. 2016; 23(11): T155–T168.
  18. Gillan L, Matei D, Fishman DA, et al. Periostin secreted by epithelial ovarian carcinoma is a ligand for alpha(V)beta(3) and alpha(V)beta(5) integrins and promotes cell motility. Cancer Res. 2002; 62(18): 5358–5364.
  19. Zhu M, Fejzo M, Anderson L, et al. Periostin promotes ovarian cancer angiogenesis and metastasis. Gynecologic Oncology. 2010; 119(2): 337–344.
  20. Choi K, Yun J, Lee I, et al. Lysophosphatidic acid-induced expression of periostin in stromal cells: Prognoistic relevance of periostin expression in epithelial ovarian cancer. International Journal of Cancer. 2010; 128(2): 332–342.
  21. Abbott K, Lim JM, Wells L, et al. Identification of candidate biomarkers with cancer-specific glycosylation in the tissue and serum of endometrioid ovarian cancer patients by glycoproteomic analysis. PROTEOMICS. 2009; 10(3): 470–481.
  22. Tian Y, Yao Z, Roden R, et al. Identification of glycoproteins associated with different histological subtypes of ovarian tumors using quantitative glycoproteomics. PROTEOMICS. 2011; 11(24): 4677–4687.
  23. Zhu M, Saxton RE, Ramos L, et al. Neutralizing Monoclonal Antibody to Periostin Inhibits Ovarian Tumor Growth and Metastasis. Molecular Cancer Therapeutics. 2011; 10(8): 1500–1508.
  24. Karlan B, Dering J, Walsh C, et al. POSTN/TGFBI-associated stromal signature predicts poor prognosis in serous epithelial ovarian cancer. Gynecologic Oncology. 2014; 132(2): 334–342.
  25. Ryner L, Guan Y, Firestein R, et al. Upregulation of Periostin and Reactive Stroma Is Associated with Primary Chemoresistance and Predicts Clinical Outcomes in Epithelial Ovarian Cancer. Clinical Cancer Research. 2015; 21(13): 2941–2951.
  26. Tan T, Yang He, Ye J, et al. CSIOVDB: a microarray gene expression database of epithelial ovarian cancer subtype. Oncotarget. 2015; 6(41): 43843–43852.
  27. Sung PL, Jan YH, Lin SC, et al. Periostin in tumor microenvironment is associated with poor prognosis and platinum resistance in epithelial ovarian carcinoma. Oncotarget. 2015; 7(4): 4036–4047.
  28. Tang M, Liu B, Bu X, et al. Cross-talk between ovarian cancer cells and macrophages through periostin promotes macrophage recruitment. Cancer Science. 2018; 109(5): 1309–1318.
  29. Lu Z, Kamat K, Johnson B, et al. Generation of a Fully Human scFv that binds Tumor-Specific Glycoforms. Scientific Reports. 2019; 9(1).
  30. Sterzyńska K, Kaźmierczak D, Klejewski A, et al. Expression of Osteoblast-Specific Factor 2 (OSF-2, Periostin) Is Associated with Drug Resistance in Ovarian Cancer Cell Lines. International Journal of Molecular Sciences. 2019; 20(16): 3927.
  31. Kujawa K, Zembala-Nożyńska E, Cortez A, et al. Fibronectin and Periostin as Prognostic Markers in Ovarian Cancer. Cells. 2020; 9(1): 149.
  32. Morelli M, Misaggi R, Cello ADi, et al. Tissue expression and serum levels of periostin during pregnancy: a new biomarker of embryo–endometrial cross talk at implantation. European Journal of Obstetrics & Gynecology and Reproductive Biology. 2014; 175: 140–144.
  33. Freis A, Schlegel J, Kuon RJ, et al. Serum periostin levels in early in pregnancy are significantly altered in women with miscarriage. Reproductive Biology and Endocrinology. 2017; 15(1).
  34. Song Hj, Zhang P, Guo Xj, et al. The proteomic analysis of human neonatal umbilical cord serum by mass spectrometry. Acta Pharmacologica Sinica. 2009; 30(11): 1550–1558.
  35. Sasaki H, Roberts J, Lykins D, et al. Novel chemiluminescence assay for serum periostin levels in women with preeclampsia and in normotensive pregnant women. American Journal of Obstetrics and Gynecology. 2002; 186(1): 103–108.
  36. Dobreva M, Lhoest L, Pereira P, et al. Periostin as a Biomarker of the Amniotic Membrane. Stem Cells International. 2012; 2012: 1–10.
  37. Ivancsó I, Bohács A, Szalay B, et al. Circulating periostin level in asthmatic pregnancy. Journal of Asthma. 2016; 53(9): 900–906.
  38. Świrska J, Zwolak A, Dudzińska M, et al. Gestational diabetes mellitus — literature review on selected cytokines and hormones of confirmed or possible role in its pathogenesis. Ginekologia Polska. 2018; 89(9): 522–527.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk
tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl